Table 2. Clinicopathological characteristics of the patients with lung cancer from TCGA database (Chi-square test; P value<0.05).
| Parameters | PHLDA1 | PHLDA2 | PHLDA3 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High | Low | P value | High | Low | P value | High | Low | P value | ||||||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||||||||
| Age | 0.23 | 0.34 | 0.44 | |||||||||||||||||
| ≤50 years | 15 | 5.8 | 22 | 8.5 | 21 | 8.1 | 16 | 6.2 | 21 | 8.1 | 16 | 6.2 | ||||||||
| >50 years | 234 | 90.7 | 227 | 87.6 | 224 | 86.8 | 237 | 91.5 | 231 | 89.5 | 230 | 88.8 | ||||||||
| NA | 9 | 3.5 | 10 | 3.9 | 13 | 5.0 | 6 | 2.3 | 6 | 2.3 | 13 | 5.0 | ||||||||
| Sex | 0.76 | 0.06 | 0.23 | |||||||||||||||||
| Female | 140 | 54.3 | 137 | 52.9 | 149 | 57.8 | 128 | 49.4 | 145 | 56.2 | 132 | 51.0 | ||||||||
| Male | 118 | 45.7 | 122 | 47.1 | 109 | 42.2 | 131 | 50.6 | 113 | 43.8 | 127 | 49.0 | ||||||||
| Race Category | 0.88 | 0.44 | 0.19 | |||||||||||||||||
| American Indian or Alaska native | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 | ||||||||
| Asian | 4 | 1.6 | 4 | 1.5 | 3 | 1.2 | 5 | 1.9 | 2 | 0.8 | 6 | 2.3 | ||||||||
| Black or African American | 24 | 9.3 | 29 | 11.2 | 30 | 11.6 | 23 | 8.9 | 31 | 12.0 | 22 | 8.5 | ||||||||
| White | 194 | 75.2 | 195 | 75.3 | 187 | 72.5 | 202 | 78.0 | 196 | 76.0 | 193 | 74.5 | ||||||||
| NA | 35 | 13.6 | 31 | 12.0 | 37 | 14.3 | 29 | 11.2 | 28 | 10.9 | 38 | 14.7 | ||||||||
| Patient smoking | 0.07 | 0.40 | 0.36 | |||||||||||||||||
| Non smoker | 28 | 10.9 | 48 | 18.5 | 42 | 16.3 | 34 | 13.1 | 40 | 15.5 | 36 | 13.9 | ||||||||
| Reformed smoker (≤15 years) | 91 | 35.3 | 78 | 30.1 | 88 | 34.1 | 81 | 31.3 | 82 | 31.8 | 87 | 33.6 | ||||||||
| Reformed smoker (>15 years) | 72 | 27.9 | 63 | 24.3 | 62 | 24.0 | 73 | 28.2 | 72 | 27.9 | 63 | 24.3 | ||||||||
| Smoker | 56 | 21.7 | 63 | 24.3 | 54 | 20.9 | 65 | 25.1 | 51 | 19.8 | 68 | 26.3 | ||||||||
| NA | 11 | 4.3 | 7 | 2.7 | 12 | 4.7 | 6 | 2.3 | 13 | 5.0 | 5 | 1.9 | ||||||||
| Stage | 0.11 | 0.47 | 0.14 | |||||||||||||||||
| I/II | 205 | 79.5 | 194 | 74.9 | 195 | 75.6 | 204 | 78.8 | 206 | 79.8 | 193 | 74.5 | ||||||||
| III/IV | 47 | 18.2 | 63 | 24.3 | 58 | 22.5 | 52 | 20.1 | 48 | 18.6 | 62 | 23.9 | ||||||||
| NA | 6 | 2.3 | 2 | 0.8 | 5 | 1.9 | 3 | 1.2 | 4 | 1.6 | 4 | 1.5 | ||||||||
| ALK translocation status | 0.45 | 0.18 | 0.58 | |||||||||||||||||
| No | 106 | 41.1 | 105 | 40.5 | 107 | 41.5 | 104 | 40.2 | 113 | 43.8 | 98 | 37.8 | ||||||||
| Yes | 20 | 7.8 | 15 | 5.8 | 22 | 8.5 | 13 | 5.0 | 17 | 6.6 | 18 | 6.9 | ||||||||
| NA | 132 | 51.2 | 139 | 53.7 | 129 | 50.0 | 142 | 54.8 | 128 | 49.6 | 143 | 55.2 | ||||||||
| KRAS mutation | 0.13 | 0.87 | 0.87 | |||||||||||||||||
| No | 20 | 7.8 | 20 | 7.7 | 20 | 7.8 | 20 | 7.7 | 20 | 7.8 | 20 | 7.7 | ||||||||
| Yes | 16 | 6.2 | 7 | 2.7 | 11 | 4.3 | 12 | 4.6 | 12 | 4.7 | 11 | 4.2 | ||||||||
| NA | 222 | 86.0 | 232 | 89.6 | 227 | 88.0 | 227 | 87.6 | 226 | 87.6 | 228 | 88.0 | ||||||||
| Expression subtype† | 0.02 | <0.01 | <0.01 | |||||||||||||||||
| Bronchioid | 48 | 18.6 | 41 | 15.8 | 36 | 14.0 | 53 | 20.5 | 56 | 21.7 | 33 | 12.7 | ||||||||
| Magnoid | 25 | 9.7 | 38 | 14.7 | 20 | 7.8 | 43 | 16.6 | 19 | 7.4 | 44 | 17.0 | ||||||||
| Squamoid | 49 | 19.0 | 29 | 11.2 | 60 | 23.3 | 18 | 6.9 | 43 | 16.7 | 35 | 13.5 | ||||||||
| NA | 136 | 52.7 | 151 | 58.3 | 142 | 55.0 | 145 | 56.0 | 140 | 54.3 | 147 | 56.8 | ||||||||
†, according to Song et al. [2018] (25). PHLDA, pleckstrin homology domain family A; NA, not available.